Wells Fargo raised the firm’s price target on Apellis (APLS) to $29 from $26 and keeps an Equal Weight rating on the shares. The firm thinks Street’s early estimates for the pegcetacoplan’s launch in C3G/IC-MPGN may be conservative. That said, Wells awaits approval on the June 28 PDUFA and base biz stability before considering getting more constructive.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Cautious Hold on Apellis Pharmaceuticals Amid Uncertainties with Pegcetacoplan Launch and Financial Stability
- Apellis price target lowered to $41 from $49 at Citi
- Apellis price target lowered to $20 from $30 at Mizuho
- Buy Recommendation for Apellis Pharmaceuticals Driven by Syfovre’s Market Potential and Strategic Expansion
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls